Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience.
about
Complementary and Alternative Medicine Use and Its Association with Emotional Status and Quality of Life in Patients with a Solid Tumor: A Cross-Sectional Study.Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center.A survey of complementary and alternative medicine use in cancer patients treated with radiotherapy in ThailandCancer-related stress and complementary and alternative medicine: a reviewComplementary and alternative medicine use among patients with cancer in Mongolia: a National hospital survey.Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells.Integrative Therapy Use for Management of Side Effects and Toxicities Experienced by Pediatric Oncology Patients.The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer.Use of Complementary Traditional Chinese Medicines by Adult Cancer Patients in Taiwan: A Nationwide Population-Based Study.Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network.Complementary and alternative medicine use among patients with thoracic malignancies.Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy.Complementary and Alternative Medicine Use in Minority and Medically Underserved Oncology Patients: Assessment and Implications.Massage Therapy in Outpatient Cancer Care: A Metropolitan Area Analysis.The impact of religiosity and individual prayer activities on advanced cancer patients' health: is there any difference in function of whether or not receiving palliative anti-neoplastic therapy?Survey on the worldwide Chronic Myeloid Leukemia Advocates Network regarding complementary and alternative medicine.Managing Drug Interactions in Cancer Therapy: A Guide for the Advanced Practitioner
P2860
Q33733423-11FCDEAF-48E7-4B24-A973-0FC20722E011Q34308310-4F3D732F-9C95-42E1-942E-B2B52A2DAB98Q35811162-95B52957-632E-4500-81EB-DEDA721A0A82Q36111505-0C75F345-2367-48FA-AD72-7AD5313BA53CQ36254532-148533DC-AFC1-4B5C-961D-5ECAB9A87F79Q36476234-19075D2F-F9BB-437D-B2E3-1B69FCBE69E5Q37055855-55A7D3B7-6D2B-4CC1-9C01-62AE45A101A0Q37190293-22499255-C323-4792-B5E1-5021A40C47CCQ38700483-21839EC8-8BB7-4D54-BE52-E4B7497F85E5Q38884752-92811453-708F-46CF-9099-C985E13D861BQ39247736-21F23C50-C516-43CB-9E2B-1EA8F7E7E8F7Q43679493-DB77DDFA-CDC2-497F-98CB-F692BC0F6A6BQ46489188-51A05AED-D905-4D9E-8C47-AF76A320BE96Q48055245-443C57BC-CFA6-4520-B4B2-A835B45FCB8DQ48179088-6433F1F6-E289-42F5-BC19-EDB59F6F41EBQ51824407-9F50AB1A-B5AC-4550-BEF7-6951E77DB5B5Q57498748-89C30E34-A9A3-45D8-B033-07B7EDA8158B
P2860
Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Prevalence of complementary me ...... rson Cancer Center Experience.
@en
Prevalence of complementary me ...... rson Cancer Center Experience.
@nl
type
label
Prevalence of complementary me ...... rson Cancer Center Experience.
@en
Prevalence of complementary me ...... rson Cancer Center Experience.
@nl
prefLabel
Prevalence of complementary me ...... rson Cancer Center Experience.
@en
Prevalence of complementary me ...... rson Cancer Center Experience.
@nl
P2093
P2860
P356
P1433
P1476
Prevalence of complementary me ...... rson Cancer Center Experience.
@en
P2093
Chandtip Chandhasin
David S Hong
Gerald Falchook
Jennifer J Wheler
Moshe Frenkel
Saneese K Stephen
Xiudong Lei
P2860
P304
P356
10.1002/CNCR.26164
P407
P577
2011-04-28T00:00:00Z